Screener
Vor Biopharma VOR EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Vor Biopharma’s reported figures.
The source filing: Vor Biopharma’s 10-Q, filed May 13, 2026. Open the filing →
- Filed
- May 13, 2026, 8:31 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-220689
FAQ
- What is Vor Biopharma's EBITDA?
- Vor Biopharma (VOR) reported EBITDA of -$35.13M in Q1 2026.
- How has Vor Biopharma's EBITDA changed year-over-year?
- Vor Biopharma's EBITDA decreased by 8.2% year-over-year, from -$32.47M to -$35.13M.
- What is the long-term trend for Vor Biopharma's EBITDA?
- Over 4 years (2021 to 2025), Vor Biopharma's EBITDA has grown at a 52.8% compound annual growth rate (CAGR), from -$67.61M to -$368.69M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Vor Biopharma's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude